Evidence map›Paper›PMID 29021226›Full record

ArticleAmerican journal of physiology. Renal physiology2018

Attenuation of accelerated renal cystogenesis in Pkd1 mice by renin-angiotensin system blockade.

Wayne R Fitzgibbon, Yujing Dang, Marlene A Bunni, Catalin F Baicu, Michael R Zile, Adam E Mullick, Takamitsu Saigusa

Open access · bronzeAbstract read
In one paragraph

Article in American journal of physiology. Renal physiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Renal Ciliopathies: Sorting Out Therapeutic Approaches for Nephronophthisis.Frontiers in cell and developmental biology · 2021
    Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Wayne R FitzgibbonDivison of Nephrology, Medical University of South Carolina , Charleston, South Carolina.
Yujing DangDivison of Nephrology, Medical University of South Carolina , Charleston, South Carolina.
Marlene A BunniDivison of Nephrology, Medical University of South Carolina , Charleston, South Carolina.
Catalin F BaicuDivision of Cardiology, Medical University of South Carolina, Ralph H. Johnson Veterans Affairs Medical Center , Charleston, South Carolina.
Michael R ZileDivision of Cardiology, Medical University of South Carolina, Ralph H. Johnson Veterans Affairs Medical Center , Charleston, South Carolina.
Adam E MullickIonis Pharmaceuticals, Inc. , Carlsbad, California.
Takamitsu SaigusaDivison of Nephrology, Medical University of South Carolina , Charleston, South Carolina.
Medical University of South Carolina · USIonis Pharmaceuticals (United States) · USRalph H. Johnson VA Medical Center · US

Funding

Research BaseP30DK090868 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · PI SELIGER, STEPHEN L. · 2010 to 2019
$11.1M
Extracellular Matrix in Hypertensive Heart Disease & Transition to Heart FailureR01HL123478 · NHLBI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI ZILE, MICHAEL R · 2015 to 2018
$1.5M
Renal Mechanism for Hypertension in Polycistic Kidney DiseaseK08DK106465 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SAIGUSA, TAKAMITSU · 2015 to 2019
$816k
NHLBI NIH HHS R01 HL123478NIDDK NIH HHS K08 DK106465NIDDK NIH HHS P30 DK090868
6 · The paper itself

Abstract

The intrarenal renin angiotensin system (RAS) is activated in polycystic kidney disease. We have recently shown in the Pkd1 mouse that Gen 2 antisense oligonucleotide (ASO), which suppresses angiotensinogen (Agt) synthesis, is efficacious in slowing kidney cyst formation compared with lisinopril. The aim of this current study was to determine 1) if unilateral nephrectomy accelerates cystogenesis in Pkd1 mice (as previously shown in cilia knockout mice) and 2) whether Agt ASO can slow the progression in this accelerated cystic mouse model. Adult Pkd1 conditional floxed allele mice expressing cre were administered tamoxifen, resulting in global knockout of Pkd1. Three weeks after tamoxifen injection, mice underwent left unilateral nephrectomy. Mice were then treated with Agt ASO (75 mg/kg per week) or aliskiren (20 mg/kg per day)+Agt ASO or control for 8 wk. Unilateral nephrectomy accelerated kidney cyst formation compared with nonnephrectomized mice. Both Agt ASO and Aliskiren+Agt ASO treatments significantly reduced plasma and urinary Agt levels. Blood pressure was lowest in Aliskiren+Agt ASO mice among all treatment groups, and the control group had the highest blood pressure. All mice developed significant kidney cysts at 8 wk after nephrectomy, but Agt ASO and Aliskiren+Agt ASO groups had fewer kidney cysts than controls. Renal pAkt, pS6 levels, and apoptosis were significantly suppressed in those receiving Agt ASO compared with controls. These results indicate that suppressing Agt using an ASO slowed the progression of accelerated cystic kidney disease induced by unilateral nephrectomy in Pkd1 mice by suppressing intrarenal RAS, mammalian target of rapamycin pathway, and cell proliferation.

Indexed as

Renin InhibitorsAmidesAngiotensinogenAnimalsApoptosisCell ProliferationDisease Models, AnimalDisease ProgressionErbB ReceptorsFemaleFumaratesGenetic Predisposition to DiseaseKidneyMaleMice, KnockoutNephrectomyAgt protein, mousealiskirenAmidesAngiotensinogenEGFR protein, mouseErbB ReceptorsFumaratesmTOR protein, mouseOligonucleotides, AntisenseReninRenin InhibitorsTOR Serine-Threonine KinasesTRPP Cation ChannelsADPKD, angiotensinogenoligonucleotidepolycystic kidney disease

Identifiers

PMID29021226
PMCPMC5866454
OpenAlexW2763046158

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.